New study tests RSV prevention drug safety in vulnerable infants
NCT ID NCT06851806
First seen Nov 17, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This study checks the safety of palivizumab, a medicine given as monthly shots to prevent severe RSV lung infections in infants under 2 years old who are at high risk. About 138 children will receive up to 5 injections, and researchers will monitor for side effects. The goal is to ensure the drug is safe for premature babies and those with certain heart or lung conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGHyderabad, 500084, India
-
Research Site
NOT_YET_RECRUITINGPune, 411006, India
Conditions
Explore the condition pages connected to this study.